MX2022006881A - Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. - Google Patents

Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.

Info

Publication number
MX2022006881A
MX2022006881A MX2022006881A MX2022006881A MX2022006881A MX 2022006881 A MX2022006881 A MX 2022006881A MX 2022006881 A MX2022006881 A MX 2022006881A MX 2022006881 A MX2022006881 A MX 2022006881A MX 2022006881 A MX2022006881 A MX 2022006881A
Authority
MX
Mexico
Prior art keywords
ox40l
variable domains
single variable
polypeptides
immunoglobulin single
Prior art date
Application number
MX2022006881A
Other languages
English (en)
Inventor
Heidi Rommelaere
Peter Florian
Thomas Leeuw
Ann Brigé
Sigrid Cornelis
Eric Lorent
Karen Heyninck
Thomas Kreutzberg
Alp Oezen Sercan
Gertrud Sibenhorn
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2022006881A publication Critical patent/MX2022006881A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente tecnología tiene como objetivo proporcionar un nuevo tipo de fármaco para tratar a un sujeto que padece una enfermedad autoinmunitaria o una enfermedad inflamatoria. Específicamente, la presente tecnología proporciona polipéptidos que comprenden al menos cuatro dominios variables únicos de inmunoglobulina (ISVD), caracterizados por que al menos dos ISVD se unen a TNFa y al menos dos ISVD se unen a OX40L. La presente tecnología también proporciona ácidos nucleicos, vectores y composiciones.
MX2022006881A 2019-12-06 2020-12-03 Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. MX2022006881A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944661P 2019-12-06 2019-12-06
EP20305071 2020-01-28
PCT/EP2020/084431 WO2021110817A1 (en) 2019-12-06 2020-12-03 Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l

Publications (1)

Publication Number Publication Date
MX2022006881A true MX2022006881A (es) 2022-07-11

Family

ID=73698854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006881A MX2022006881A (es) 2019-12-06 2020-12-03 Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.

Country Status (13)

Country Link
US (1) US20210188986A1 (es)
EP (1) EP4069293A1 (es)
JP (1) JP2023505490A (es)
KR (1) KR20220111313A (es)
CN (1) CN114980923A (es)
AU (1) AU2020397210A1 (es)
BR (1) BR112022010231A2 (es)
CA (1) CA3163764A1 (es)
CO (1) CO2022008576A2 (es)
IL (1) IL293554A (es)
MX (1) MX2022006881A (es)
TW (1) TW202134270A (es)
WO (1) WO2021110817A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220153854A1 (en) * 2020-09-25 2022-05-19 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
CN116183472B (zh) * 2023-04-25 2023-08-18 上海益诺思生物技术股份有限公司 Cba法检测非人类灵长类动物细胞因子的验证方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1999023221A2 (en) 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2006122787A1 (en) * 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
WO2007118670A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. Dp-78-like nanobodies
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US8962807B2 (en) * 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2012175741A2 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9573992B2 (en) 2011-06-23 2017-02-21 Ablynx N.V. Serum albumin binding proteins
JP7325928B2 (ja) 2014-05-16 2023-08-15 アブリンクス エン．ヴェー． 改善された免疫グロブリン可変ドメイン
NO2768984T3 (es) 2015-11-12 2018-06-09
PL3374392T3 (pl) 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
CA3005488A1 (en) * 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
CN110049997B (zh) 2016-12-07 2023-09-22 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
WO2018131234A1 (ja) 2017-01-16 2018-07-19 株式会社村田製作所 ピエゾ抵抗素子、力学量検知センサおよびマイクロフォン
US11414481B2 (en) 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
BR112019014600A2 (pt) 2017-01-17 2020-02-18 Ablynx N.V. Ligantes de albumina sérica melhorados

Also Published As

Publication number Publication date
WO2021110817A1 (en) 2021-06-10
BR112022010231A2 (pt) 2022-09-06
CO2022008576A2 (es) 2022-07-08
JP2023505490A (ja) 2023-02-09
TW202134270A (zh) 2021-09-16
US20210188986A1 (en) 2021-06-24
CN114980923A (zh) 2022-08-30
CA3163764A1 (en) 2021-06-10
AU2020397210A1 (en) 2022-07-28
KR20220111313A (ko) 2022-08-09
IL293554A (en) 2022-08-01
EP4069293A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
MX2019006574A (es) Aglutinantes de albumina de suero mejorados.
EA201892691A1 (ru) Однодоменный белок, связывающий сывороточный альбумин
MY190209A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
MX2019008536A (es) Aglutinantes de albumina serica mejorados.
PH12021550802A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2019157366A8 (en) Antibody variable domains targeting the nkg2d receptor
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2022006881A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
WO2006038027A3 (en) SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR
MX2022005404A (es) Compuestos de fijación a il-2r e il-7r dual.
PH12020500137A1 (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
WO2019020774A3 (en) NOVEL ANTIBODIES AND COMBINED USE OF ANTIBODY THAT INDUCES TREG DEPLOYMENT AND AN IMMUNOSTIMULATOR ANTIBODY
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
MX2022003432A (es) Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada.
MX2022006880A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.
MX2022003074A (es) Anticuerpos anti-cd371, y usos de los mismos.
MX2023007308A (es) Polipeptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de celulas t.